Overview

The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the risk of incident heart failure associated with the use of pramipexole compared with other dopamine agonists and additionally, to assess the risk of incident heart failure associated with the use of dopamine agonists in comparison with no use of dopamine agonist therapy
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Dopamine
Dopamine Agonists
Pramipexole